2qe4: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Estrogen receptor alpha ligand-binding domain in complex with a benzopyran agonist== | ==Estrogen receptor alpha ligand-binding domain in complex with a benzopyran agonist== | ||
<StructureSection load='2qe4' size='340' side='right' caption='[[2qe4]], [[Resolution|resolution]] 2.40Å' scene=''> | <StructureSection load='2qe4' size='340' side='right' caption='[[2qe4]], [[Resolution|resolution]] 2.40Å' scene=''> | ||
Line 6: | Line 7: | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2q70|2q70]], [[2i0j|2i0j]], [[2pog|2pog]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2q70|2q70]], [[2i0j|2i0j]], [[2pog|2pog]]</td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ESR1, ESR, NR3A1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ESR1, ESR, NR3A1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2qe4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2qe4 OCA], [http://pdbe.org/2qe4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2qe4 RCSB], [http://www.ebi.ac.uk/pdbsum/2qe4 PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2qe4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2qe4 OCA], [http://pdbe.org/2qe4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2qe4 RCSB], [http://www.ebi.ac.uk/pdbsum/2qe4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2qe4 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
Line 14: | Line 15: | ||
Check<jmol> | Check<jmol> | ||
<jmolCheckbox> | <jmolCheckbox> | ||
<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/qe/2qe4_consurf.spt"</scriptWhenChecked> | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/qe/2qe4_consurf.spt"</scriptWhenChecked> | ||
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | ||
<text>to colour the structure by Evolutionary Conservation</text> | <text>to colour the structure by Evolutionary Conservation</text> | ||
Line 49: | Line 50: | ||
[[Category: Ryter, K T]] | [[Category: Ryter, K T]] | ||
[[Category: Wang, Y]] | [[Category: Wang, Y]] | ||
[[Category: Alternative splicing]] | |||
[[Category: Dna-binding]] | [[Category: Dna-binding]] | ||
[[Category: Ligand-binding domain]] | [[Category: Ligand-binding domain]] | ||
Line 56: | Line 58: | ||
[[Category: Nuclear receptor]] | [[Category: Nuclear receptor]] | ||
[[Category: Phosphorylation]] | [[Category: Phosphorylation]] | ||
[[Category: Polymorphism]] | |||
[[Category: Steroid-binding]] | [[Category: Steroid-binding]] | ||
[[Category: Transcription]] | [[Category: Transcription]] | ||
[[Category: Transcription regulation]] | [[Category: Transcription regulation]] | ||
[[Category: Zinc]] | |||
[[Category: Zinc-finger]] | [[Category: Zinc-finger]] |
Revision as of 11:41, 29 August 2018
Estrogen receptor alpha ligand-binding domain in complex with a benzopyran agonistEstrogen receptor alpha ligand-binding domain in complex with a benzopyran agonist
Structural highlights
Function[ESR1_HUMAN] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedBenzopyrans are selective estrogen receptor (ER) beta agonists (SERBAs), which bind the ER receptor subtypes alpha and beta in opposite orientations. We have used structure based drug design to show that this unique phenomena can be exploited via substitution at the 8-position of the benzopyran A-ring to disrupt binding to ERalpha, thus improving ERbeta subtype selectivity. X-ray cocrystal structures with ERalpha and ERbeta are supportive of this approach to improve selectivity in this structural class. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring.,Norman BH, Richardson TI, Dodge JA, Pfeifer LA, Durst GL, Wang Y, Durbin JD, Krishnan V, Dinn SR, Liu S, Reilly JE, Ryter KT Bioorg Med Chem Lett. 2007 Sep 15;17(18):5082-5. Epub 2007 Jul 13. PMID:17662603[19] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Human
- Dinn, S R
- Dodge, J A
- Durbin, J D
- Durst, G L
- Krishnan, V
- Liu, S Q
- Norman, B H
- Pfeifer, L A
- Reilly, J E
- Richardson, T I
- Ryter, K T
- Wang, Y
- Alternative splicing
- Dna-binding
- Ligand-binding domain
- Lipid-binding
- Metal-binding
- Nuclear protein
- Nuclear receptor
- Phosphorylation
- Polymorphism
- Steroid-binding
- Transcription
- Transcription regulation
- Zinc
- Zinc-finger